FDA Webview
X
about-us-banner

FDA Related News

Home / Articles / FDA Related News
latest-news-card-1
Human Drugs

FDA Approves Ipsens Pancreatic Cancer Drug

FDA approves an Ipsen Biopharmaceuticals NDA for Onivyde (irinotecan liposome) for use in combination with oxaliplatin, fluorouracil, and leucovorin f...

latest-news-card-1
Federal Register

5-Year Debarment for Ross Lucien

Federal Register notice: FDA issues an order debarring Ross Lucien for five years from importing any drug into the U.S.

latest-news-card-1
Federal Register

Kalpen Patel Debarred by FDA

Federal Register notice: FDA issues an order to permanently debar Kalpen D. Patel from providing services in any capacity to a person that has an appr...

latest-news-card-1
Federal Register

Data Monitoring Draft Guidance Released

Federal Register notice: FDA releases a draft guidance entitled Use of Data Monitoring Committees in Clinical Trials.

latest-news-card-1
Human Drugs

FDA Warns 2 Firms Over Illegal Weight-Loss Drugs

FDA warns Miami, FL-based US Chem Labs and Bronx, NY-based Helix Chemical that they are selling unapproved and misbranded versions of the popular bran...

latest-news-card-1
Human Drugs

ICH Draft Guide on Post-Approval Safety Data

FDA publishes an ICH draft guideline on post-approval safety data that is available for comment.

Medical Devices

Nanox Fatty Liver Detector Cleared by FDA

FDA clears a Nanox AI 510(k) for HealthFLD, an artificial intelligence software that provides automated qualitative and quantitative analysis of liver...

latest-news-card-1
Medical Devices

FDA Getting Stricter on Cybersecurity Enforcement

Former FDAer Naomi Schwartz says medical device companies must prioritize cybersecurity compliance to meet a stricter FDA enforcement emphasis.

latest-news-card-1
Medical Devices

FDA Clears Masimo OTC Pulse Oximeter

FDA clears a Masimo 510(k) for its MightySat Medical, an over-the-counter fingertip pulse oximeter.

latest-news-card-1
Human Drugs

FDA Issues Data Monitoring Committee Draft Guide

FDA makes available a draft guidance entitled Use of Data Monitoring Committees in Clinical Trials.